${\bf Supporting\ Information\ } for$

Elemental tellurium mediated synthesis 2-(trifluoromethyl)oxazoles using trifluoroacetic anhydride as reagent

Beibei Luo, and Zhiqiang Weng*

State Key Laboratory of Photocatalysis on Energy and Environment, College of Chemistry, Fuzhou University, Fujian 350108, China.

E-mail: zweng@fzu.edu.cn

Table of Contents

General information	2				
General procedure for preparation of oxime acetates substrates	3				
General procedure of the tellurium-mediated synthesis of	1				
2-(trifluoromethyl)oxazoles					
Procedure for the synthesis of 4-phenyl-2-(trifluoromethyl)oxazole (3a) on a 10.0	5				
mmol scale	3				
Experiments for Mechanistic Investigations	6				
The procedure for the biological assay	10				
Data for compounds 3	14				
Crystal structure analyses	29				
References	31				
Copies of ¹ H NMR, ¹⁹ F NMR and ¹³ C NMR spectra					

General information

 1 H NMR, 19 F NMR and 13 C NMR spectra were recorded using Bruker AVIII 400 spectrometer. 1 H NMR and 13 C NMR chemical shifts were reported in parts per million (ppm) downfield from tetramethylsilane and 19 F NMR chemical shifts were determined relative to CFCl₃ as the external standard and low field is positive. Coupling constants (J) are reported in Hertz (Hz). The residual solvent peak was used as an internal reference: 1 H NMR (chloroform δ 7.26) and 13 C NMR (chloroform δ 77.0). The following abbreviations were used to explain the multiplicities: s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet, p = broad. HRMS were obtained on Waters GCT-TOF at the Shanghai Institute of Organic Chemistry and State Key Discipline Testing Center for Physical Chemistry of Fuzhou University. Reagents were received from commercial sources. Solvents were freshly dried and degassed according to the published procedures prior to use. Column chromatography purifications were performed by flash chromatography using Merck silica gel 60.

General procedure for preparation of oxime acetate substrates

Oxime acetates were synthesized according to the published procedures: 1-6

To a solution of aromatic ketones (2 mmol) in the mixture of C_2H_5OH/H_2O (v/v = 1:1) was added hydroxylamine hydrochloride (2.2 mmol), NaOAc (3 mmol) in one portion, and the reaction mixture was stirred at 100 °C for 6 h. Upon completion of the reaction as indicated by TLC, the reaction mixture was diluted with water, and extracted with ethyl acetate (15 mL \times 3), dried over MgSO₄. The solvent was removed under reduced pressure to give oximes.

The mixture of aromatic ketoxime (2.0 mmol), anhydride (4.0 mmol) was stirred at 100 °C for 3 h. Upon completion of the reaction as indicated by TLC, the reaction mixture was diluted with water, and extracted with ethyl acetate (15 mL × 3), dried over MgSO₄. The solvent was removed by rotary evaporation and the resulting product was purified by column chromatography over silica gel with hexanes as the eluent to afford aromatic ketoxime acetates.

General procedure of the tellurium-mediated synthesis of 2-(trifluoromethyl)oxazoles

The aromatic ketoxime acetates derivatives (1) (1.0 mmol), trifluoroacetic anhydride (2) (2.0 mmol, 2.0 equiv), Te (1.0 mmol, 1.0 equiv), I_2 (0.2 mmol, 0.2 equiv), and toluene (4.0 mL) were added to a oven-dried 25.0 mL test tube with Teflon screw cap. The tube was sealed and the mixture solution was placed into a preheated 120 °C oil bath for 4 h. The tube was removed from the oil bath and cooled to r.t. The reaction mixture was diluted with ethyl acetate (15 mL \times 3), washed with saturated sodium bicarbonate (30 mL), and water (20 mL), dried over MgSO₄. The solvent was removed by rotary evaporation and the resulting crude product 3 was purified by column chromatography over silica gel (n-pentanes).

Procedure for the synthesis of 4-phenyl-2-(trifluoromethyl)oxazole (3a) on a 10.0 mmol scale

OAc
$$F_3$$
 F_3 C CF_3 F_3 C F_3

The acetophenone oxime acetate (1a) (1.77 g, 10.0 mmol), trifluoroacetic anhydride (2) (2.8 mL, 4.20 g, 20.0 mmol, 2.0 equiv), Te (1.30 g, 10.0 mmol), I₂ (0.50 g, 2.0 mmol), and toluene (40.0 mL) were added to a oven-dried 100 mL test tube with Teflon screw cap. The tube was sealed and the mixture solution was placed into a preheated 120 °C oil bath for 4 h. The tube was removed from the oil bath and cooled to r.t. The reaction mixture was diluted with ethyl acetate (40 mL × 5), washed with saturated sodium bicarbonate (500 mL), and water (200 mL), dried over MgSO₄. The solvent was removed by rotary evaporation and the crude product was purified by column chromatography silica (*n*-pentanes). The over gel product 4-phenyl-2-(trifluoromethyl)oxazole (3a) was isolated as a white solid in 71% (1.52) g).

Experiments for Mechanistic Investigations

(a) Competition reaction of ketoxime acetates derivatives 1ae and 1ag with 2.

The aromatic ketoxime acetates derivatives **1ad** (17.7 mg, 0.10 mmol), **1ag** (21.7 mg, 0.10 mmol), trifluoroacetic anhydride (**2**) (42 μ L, 63 mg, 0.30 mmol), Te (13 mg, 0.10 mmol), I₂ (5.0 mg, 0.020 mmol), and 1.0 mL toluene were added to a oven-dried 5 mL test tube with Teflon screw cap. The tube was sealed and the mixture solution was placed into a preheated 120 °C oil bath for 4 h. The tube was removed from the oil bath and cooled to r.t. 10 μ L (Trifluoromethoxy)benzene was then added as an internal standard. The reaction mixture was filtered through a layer of celite. The filtrate was analyzed by ¹⁹F NMR and GC-MS, and the products **3ad** and **3ag** were calculated to be 45% and 9%, respectively.

(b) Procedure for the reaction of acetophenone oxime acetate (1a) with trifluoroacetic anhydride (2) mediated by tellurium in the presence of 2.0 equiv TEMPO

In a dry-box, acetophenone oxime acetate (**1a**) (177 mg, 1.0 mmol), trifluoroacetic anhydride (**2**) (280 μ L, 420 mg, 2.0 mmol, 2.0 equiv), Te (130 mg, 1.0 mmol, 1.0 equiv), I₂ (50 mg, 0.20 mmol, 0.20 equiv), TEMPO (312 mg, 2.0 mmoL, 2.0 equiv), and 1.0 mL toluene were added to a oven-dried 5 mL test tube with Teflon screw cap. The tube was sealed and the mixture solution was placed into a preheated 120 °C oil bath for 4 h. The tube was removed from the oil bath and cooled to r.t. 10 μ L (Trifluoromethoxy)benzene was then added as an internal standard. The reaction mixture was filtered through a layer of celite. The filtrate was analyzed by ¹⁹F NMR and GC-MS, and no trace of 4-phenyl-2-(trifluoromethyl)oxazole (**3a**) was detected. Compound 2,2,2-trifluoro-*N*-(1-phenylethylidene)acetamide (**4**) was formed in 85% NMR yield.

(c) Procedure for the reaction of acetophenone oxime acetate (1a) with trifluoroacetic anhydride mediated by tellurium in the presence of 2.0 equiv BHT

In a dry-box, acetophenone oxime acetate (**1a**) (177 mg, 1.0 mmol), trifluoroacetic anhydride (**2**) (280 μ L, 420 mg, 2.0 mmol, 2.0 equiv), Te (130 mg, 1.0 mmol, 1.0 equiv), I₂ (50 mg, 0.20 mmol, 0.20 equiv), BHT (441 mg, 2.0 mmoL, 2.0 equiv), and 4.0 mL toluene were added to a oven-dried 25 mL test tube with Teflon screw cap. The tube was sealed and the mixture solution was placed into a preheated 120 °C oil bath for 4 h. The tube was removed from the oil bath and cooled to r.t. 10 μ L (Trifluoromethoxy)benzene was then added as an internal standard. The reaction mixture was filtered through a layer of celite. The filtrate was analyzed by ¹⁹F NMR and GC-MS, and the yields of 4-phenyl-2-(trifluoromethyl)oxazole (**3a**) and BHT-adduct (**5**) were calculated to be 7% and 16%, respectively.

The reaction mixture was diluted with ethyl acetate (15 mL × 3), washed with saturated sodium bicarbonate (30 mL), and water (20 mL), dried over MgSO₄. The solvent was removed by rotary evaporation and the resulting product **7** was purified by column chromatography over silica gel (n-pentane/ethyl acetate = 10:1). N-(2-(2,6-di-tert-butyl-4-methylphenoxy)-1-phenylethylidene)-2,2,2-trifluoroacetami de (**5**): Obtained as a light yellow solid. M.p. 141–142 °C. R_f (n-pentane/ethyl acetate = 10:1) = 0.52. ¹H NMR (400 MHz, CDCl₃) δ 7.47 – 7.35 (m, 6H), 7.22 (s, 2H), 6.26 (t, J = 7.2 Hz, 1H), 3.50 (d, J = 7.0 Hz, 2H), 2.38 (s, 3H), 1.38 (s, 18H). ¹⁹F NMR (376 MHz, CDCl₃) δ -75.1 (s, 3F). ¹³C NMR (101 MHz, CDCl₃) δ 171.3 (s), 155.3 (q, J = 37.0 Hz), 146.6 (s), 142.7 (s), 136.0 (s), 135.8 (s), 131.2 (s), 128.8 (s), 128.7 (s), 127.2 (s), 126.6 (s), 125.6 (s), 115.9 (q, J = 289.1 Hz), 35.4 (s), 34.5 (s), 31.5 (s), 22.7 (s). IR (KBr): v 3277, 2964, 2165, 2034, 1717, 1526, 1483, 1425, 1367, 1203, 1164,

804, 758, 694, 515 cm $^{-1}$. GC-MS m/z 475 (M $^{+}$). HRMS (EI) m/z: calcd. for $C_{27}H_{32}F_3NO_3$: 475.2334; found: 475.2324.

A proposed reaction pathway for the formation of 5

$$\begin{array}{c} CF_3 \\ N \\ O \\ \end{array}$$

The procedure for the biological assay

Evaluations of fungicidal activities of the synthesized compounds:

Each of the test compounds (4 mg) was first dissolved in 5 mL of mixture of acetone and methanol (1:1 by volume), and then 5 mL of water containing 0.1% Tween 80 was added to generate a 10 mL stock solution of 400 mg/L concentration.

Briefly, a whole plant is used in this test, and the testing solution is sprayed to the host plant by a special plant sprayer. The plant is inoculated with fungus after 24 h. According to the infecting characteristics of fungus, the plant is stored in a humidity chamber and then transferred into a greenhouse after infection is finished. The other plants are placed in a greenhouse directly. The activity of each compound was estimated by visual inspection after 7 days, and screening results were reported as a range from 0% (no control) to 100% (complete control).

The general screening of the title compounds on bactericidal activity

1	bactericidal activity (% control at the concentration of 400 mg/L)				
compound	CDM	WPM	CSR	CA	
CF ₃	0	0	0	0	
MeS 3h	0	60	20	0	
N=O N=O S 3s	0	30	0	0	
CF ₃	0	0	60	0	
CF ₃	0	0	75	0	
MeO 3af	0	0	40	0	
Mancozeb (25 mg/L)	90	-	-	-	
Azoxystrobin (25 mg/L)	-	100	100	100	

 $CDM = cucumber\ downy\ mildew;\ WPM = wheat\ powdery\ mildew;\ CSR = corn\ rust;$

CA = cucumber anthracnose

Insecticidal activities:

Each of the test compounds was first dissolved in 5 mL of mixture of acetone and methanol (1:1 by volume), and then 5 mL of water containing 0.1% Tween 80 was added to generate a 10 mL stock solution of 600 mg/L concentration.

The cabbage leaves were cut into small circular pieces ($\phi = 30$ mm), and placed on the glass Petri dishes ($\phi = 60$ mm) layered with filter papers that had been wet with sterilized distilled water. The cabbage leaves were prayed with the aforementioned solutions using a Airbrush sprayer (dosage 0.5 mL). After they were air dried, the third-instar insects were introduced to the cabbage leaves. They were kept in a special room for normal cultivation (temperature: 23-25 °C; RH: 40-60%, L/D: 13 h/11 h). Assessments were made after 72 h by the number of killed and size of live insects relative to that in the negative control, and evaluations were based on a percentage scale of 0-100, in which 100 was total kill and 0 was no activity. To compare their activities, the commercial products abamectin and imidacloprid was tested at the concentration of 10 mg/L under the same conditions.

For the insecticidal activities against leucania separate, the corn leaf disks (2 mm \times 5 mm) were used instead of the cabbage leaves.

The general screening of the title compounds on insecticidal activity

	I	.				
	insecticidal activity (% mortality at the concentration of 600 mg/L					
compound	plutella	leucania .	muzus parsiasa	tetranychus		
	xylostella	separate	myzus persicae	cinnabarinus		
CF ₃	0	0	0	0		
MeS 3h	0	0	0	0		
S 3s	0	0	0	0		
CF ₃	42.9	0	0	0		
CF ₃	0	0	0	0		
MeO 3af	16.7	0	0	0		
96.2% Abamectin (10 mg/L)	100	100	-	100		
96% Imidacloprid (10 mg/L)	-	-	100	-		

Data for compounds 3.

4-Phenyl-2-(trifluoromethyl)oxazole (3a)

Obtained as a white solid in 95% yield (202 mg). M.p. 51–52 °C. R_f (n-pentane) = 0.75. 1 H NMR (400 MHz, CDCl₃) δ 8.03 (s, 1H), 7.79 (d, J = 7.6 Hz, 2H), 7.53 – 7.37 (m, 3H). 19 F NMR (376 MHz, CDCl₃) δ -65.9 (s, 3F). 13 C NMR (101 MHz, CDCl₃) δ 150.9 (q, J = 44.0 Hz), 142.1 (s), 135.4 (q, J = 1.2 Hz), 129.2 (s), 129.1 (s), 128.9 (s), 125.8 (s), 116.5 (q, J = 270.7 Hz). IR (KBr): v 1598, 1580, 1486, 1450, 1378, 1243, 1155, 1125, 938, 754, 691, 548 cm⁻¹. GC-MS m/z 213 (M⁺). HRMS (ESI) m/z: calcd. for $C_{10}H_6F_3NO$: 213.0401; found: 213.0399.

4-(p-Tolyl)-2-(trifluoromethyl)oxazole (3b)

Obtained as a white solid in 98% yield (222 mg). M.p. 76–77 °C. R_f (n-pentane) = 0.69. ¹H NMR (400 MHz, CDCl₃) δ 8.00 (s, 1H), 7.68 (d, J = 8.2 Hz, 2H), 7.28 (d, J = 8.2 Hz, 2H), 2.42 (s, 3H). ¹⁹F NMR (376 MHz, CDCl₃) δ -65.8 (s, 3F). ¹³C NMR (101 MHz, CDCl₃) δ 150.9 (q, J = 43.9 Hz), 142.1 (s), 139.1 (s), 134.9 (q, J = 1.2 Hz), 129.6 (s), 126.4 (s), 125.7 (s), 116.5 (q, J = 270.6 Hz), 21.3 (s). IR (KBr): ν 2177, 2141, 2055, 1980, 1582, 1379, 1207, 1160, 954, 902, 822, 769, 545, 476 cm⁻¹. GC-MS m/z 227 (M⁺). HRMS (EI) m/z: calcd. for C₁₁H₈F₃NO: 227.0558; found: 227.0559.

4-(*m*-Tolyl)-2-(trifluoromethyl)oxazole (3c)

Obtained as a white solid in 82% yield (186mg). M.p. 30–31 °C. R_f (n-pentane) = 0.65. ¹H NMR (400 MHz, CDCl₃) δ 8.01 (s, 1H), 7.64 (s, 1H), 7.57 (d, J = 7.7 Hz, 1H), 7.36 (t, J = 7.6 Hz, 1H), 7.23 (d, J = 7.6 Hz, 1H), 2.44 (s, 3H). ¹⁹F NMR (376 MHz, CDCl₃) δ -65.9 (s, 3F). ¹³C NMR (101 MHz, CDCl₃) δ 150.9 (q, J = 44.0 Hz), 142.2 (s), 138.8 (s), 135.4 (q, J = 1.2 Hz), 129.9 (s), 129.1 (s), 128.8 (s), 126.5 (s), 122.9 (s), 116.5 (q, J = 270.7 Hz), 21.3 (s). IR (KBr): v 2815, 2213, 1585, 1377, 1243, 1207, 1159, 1126, 1106, 951, 836, 769, 548 cm⁻¹. GC-MS m/z 227 (M⁺). HRMS (EI) m/z: calcd. for C₁₁H₈F₃NO: 227.0558; found: 227.0548.

4-(4-(tert-Butyl)phenyl)-2-(trifluoromethyl)oxazole (3d)

Obtained as a white liquid in 97% yield (261 mg). R_f (n-pentane) = 0.75. ¹H NMR (400 MHz, CDCl₃) δ 8.01 (s, 1H), 7.78 – 7.67 (m, 2H), 7.53 – 7.47 (m, 2H), 1.40 (s, 9H). ¹⁹F NMR (376 MHz, CDCl₃) δ -65.8 (s, 3F). ¹³C NMR (101 MHz, CDCl₃) δ 152.4 (s), 150.9 (q, J = 44.0 Hz), 142.1 (s), 135.1 (q, J = 1.2 Hz), 126.4 (s), 125.9 (s), 125.6 (s), 116.5 (q, J = 270.7 Hz), 34.8 (s), 31.2 (s). IR (KBr): v 2965, 2789, 2205, 1597, 1498, 1378, 1244, 1204, 1156, 954, 939, 755, 557 cm⁻¹. GC-MS m/z 269 (M⁺). HRMS (EI) m/z: calcd. for C₁₄H₁₄F₃NO: 269.1027; found: 269.1029.

4-(4-Isobutylphenyl)-2-(trifluoromethyl)oxazole (3e)

Obtained as a white solid in 79% yield (213 mg). M.p. 40–41 °C. R_f (n-pentane) = 0.69. ¹H NMR (400 MHz, CDCl₃) δ 7.99 (s, 1H), 7.70 (d, J = 8.1 Hz, 2H), 7.25 (d, J

= 8.1 Hz, 2H), 2.55 (d, J = 7.2 Hz, 2H), 1.93 (dp, J = 13.6, 6.8 Hz, 1H), 0.97 (d, J = 6.6 Hz, 6H). ¹⁹F NMR (376 MHz, CDCl₃) δ -65.9 (s, 3F). ¹³C NMR (101 MHz, CDCl₃) δ 150.9 (q, J = 44.0 Hz), 142.9 (s), 142.2 (s), 135.0 (q, J = 1.2 Hz), 129.7 (s), 126.7 (s), 125.6 (s), 116.6 (q, J = 270.6 Hz), 45.2 (s), 30.2 (s), 22.3 (s). IR (KBr): v 2957, 2870, 1597, 1465, 1378, 1301, 1242, 1156, 1125, 1103, 953, 798, 767, 532 cm⁻¹. GC-MS m/z 269 (M⁺). HRMS (EI) m/z: calcd. for C₁₄H₁₄F₃NO: 269.1027; found: 269.1033.

4-(4-Methoxyphenyl)-2-(trifluoromethyl)oxazole (3f)

Obtained as a white solid in 71% yield (173 mg). M.p. 68–69 °C. R_f (n-pentane/ethyl acetate = 15:1) = 0.63. ¹H NMR (400 MHz, CDCl₃) δ 7.96 (s, 1H), 7.71 (d, J = 8.5 Hz, 2H), 6.99 (d, J = 8.5 Hz, 2H), 3.87 (s, 3H). ¹⁹F NMR (376 MHz, CDCl₃) δ -65.8 (s, 3F). ¹³C NMR (101 MHz, CDCl₃) δ 160.3 (s), 150.8 (q, J = 44.0 Hz), 141.9 (s), 134.4 (q, J = 1.3 Hz), 127.2 (s), 121.8 (s), 116.5 (q, J = 270.6 Hz), 114.4 (s), 55.3 (s). IR (KBr): v 2788, 2253, 2150, 1619, 1502, 1380, 1255, 1207, 1162, 939, 835, 635, 546 cm⁻¹. GC-MS m/z 243 (M⁺). HRMS (EI) m/z: calcd. for C₁₁H₈F₃NO₂: 243.0507; found: 243.0508.

4-(3-Methoxyphenyl)-2-(trifluoromethyl)oxazole (3g)

Obtained as a white solid in 62% yield (151 mg). M.p. 34–35 °C. R_f (n-pentane/ethyl acetate = 15:1) = 0.59. ¹H NMR (400 MHz, CDCl₃) δ 8.04 (s, 1H), 7.42 – 7.31 (m, 3H), 6.96 (d, J = 7.2 Hz, 1H), 3.90 (s, 3H). ¹⁹F NMR (376 MHz, CDCl₃) δ -65.8 (s, 3F). ¹³C NMR (101 MHz, CDCl₃) δ 160.1 (s), 150.9 (q, J = 44.1 Hz), 142.0 (s), 135.6

 $(q, J = 1.2 \text{ Hz}), 130.5 \text{ (s)}, 130.0 \text{ (s)}, 118.2 \text{ (s)}, 116.5 \text{ (q, } J = 270.8 \text{ Hz)}, 114.9 \text{ (s)}, 111.2 \text{ (s)}, 55.4 \text{ (s)}. IR (KBr): v 2927, 1583, 1490, 1466, 1377, 1320, 1288, 1246, 1159, 952, 838, 771, 549 cm⁻¹. GC-MS m/z 243 (M⁺). HRMS (EI) m/z: calcd. for <math>C_{11}H_8F_3NO_2$: 243.0507; found: 243.0500.

4-(4-(Methylthio)phenyl)-2-(trifluoromethyl)oxazole (3h)

Obtained as a white solid in 73% yield (189 mg). M.p. 94–95 °C. R_f (n-pentane) = 0.40. ¹H NMR (400 MHz, CDCl₃) δ 8.02 (s, 1H), 7.70 (d, J = 8.2 Hz, 2H), 7.32 (d, J = 8.2 Hz, 2H), 2.54 (s, 3H). ¹⁹F NMR (376 MHz, CDCl₃) δ -65.8 (s, 3F). ¹³C NMR (101 MHz, CDCl₃) δ 150.9 (q, J = 44.2 Hz), 141.7 (s), 140.0 (s), 135.1 (q, J = 0.9 Hz), 126.5 (s), 126.2 (s), 125.8 (s), 116.5 (q, J = 270.6 Hz), 15.5 (s). IR (KBr): v 3152, 3126, 2919, 2323, 1989, 1611, 1591, 1487, 1380, 1256, 1153, 954, 863, 756, 497 cm⁻¹. GC-MS m/z 259 (M⁺). HRMS (EI) m/z: calcd. for C₁₁H₈F₃NOS: 259.0279; found: 259.0284.

Methyl 4-(2-(trifluoromethyl)oxazol-4-yl)benzoate (3i)

Obtained as a white solid in 45% yield (122 mg). M.p. 96–97 °C. R_f (n-pentane/ethyl acetate = 15:1) = 0.50. 1 H NMR (400 MHz, CDCl₃) δ 8.17 – 8.11 (m, 3H), 7.87 (d, J = 8.3 Hz, 2H), 3.97 (s, 3H). 19 F NMR (376 MHz, CDCl₃) δ -65.9 (s, 3F). 13 C NMR (101 MHz, CDCl₃) δ 166.5 (s), 151.2 (q, J = 44.3 Hz), 141.2 (s), 136.6 (q, J = 1.2 Hz), 133.4 (s), 130.5 (s), 130.3 (s), 125.7 (s), 116.3 (q, J = 270.9 Hz), 52.3 (s). IR (KBr): ν 3126, 2960, 2920, 2852, 1709, 1616, 1594, 1475, 1381, 1284, 1134, 956, 862, 774,

 507 cm^{-1} . GC-MS m/z 271 (M^{+}). HRMS (EI) m/z: calcd. for $C_{12}H_8F_3NO_3$: 271.0456; found: 271.0457.

4-(4-Nitrophenyl)-2-(trifluoromethyl)oxazole (3j)

Obtained as a deep red solid in 40% yield (103 mg). M.p. 118–119 °C. R_f (n-pentane/ethyl acetate = 15:1) = 0.58. ¹H NMR (400 MHz, CDCl₃) δ 8.33 (d, J = 8.8 Hz, 2H), 8.24 (s, 1H), 7.98 (d, J = 8.8 Hz, 2H). ¹⁹F NMR (376 MHz, CDCl₃) δ -65.9 (s, 3F). ¹³C NMR (101 MHz, CDCl₃) δ 151.6 (q, J = 44.6 Hz), 148.0 (s), 140.2 (s), 137.3 (q, J = 1.0 Hz), 135.4 (s), 126.5 (s), 124.4 (s), 116.2 (q, J = 271.1 Hz). IR (KBr): v 3126, 2919, 2163, 2074, 1591, 1519, 1417, 1343, 1207, 1137, 939, 854, 718, 695 cm⁻¹. GC-MS m/z 258 (M⁺). HRMS (EI) m/z: calcd. for C₁₀H₅F₃N₂O₃: 258.0252; found: 258.0247.

4-(4-Fluorophenyl)-2-(trifluoromethyl)oxazole (3k)

Obtained as a white solid in 58% yield (135 mg). M.p. 35–36 °C. R_f (n-pentane/ethyl acetate = 15:1) = 0.65. ¹H NMR (400 MHz, CDCl₃) δ 8.01 (s, 1H), 7.76 (dd, J = 8.5, 5.4 Hz, 2H), 7.16 (t, J = 8.6 Hz, 2H). ¹⁹F NMR (376 MHz, CDCl₃) δ -65.9 (s, 3F), -111.7 – -111.9 (m, 1F). ¹³C NMR (101 MHz, CDCl₃) δ 164.4 (s), 161.9 (s), 151.0 (q, J = 44.2 Hz), 141.3 (s), 135.1 (s), 127.7 (d, J = 8.3 Hz), 125.4 (d, J = 3.3 Hz), 116.4 (q, J = 270.7 Hz), 116.2 (s), 115.9 (s). IR (KBr): v 2150, 2098, 1500, 1379, 1241, 1208, 1158, 1127, 1107, 904, 841, 614 cm⁻¹. GC-MS m/z 231 (M⁺). HRMS (EI) m/z: calcd. for $C_{10}H_5F_4NO$: 231.0307; found: 231.0305.

4-(4-Chlorophenyl)-2-(trifluoromethyl)oxazole (3l)

Obtained as a white liquid in 63% yield (156 mg). R_f (n-pentane) = 0.72. ¹H NMR (400 MHz, CDCl₃) δ 8.04 (s, 1H), 7.75 – 7.68 (m, 2H), 7.46 – 7.39 (m, 2H). ¹⁹F NMR (376 MHz, CDCl₃) δ -65.9 (s, 3F). ¹³C NMR (101 MHz, CDCl₃) δ 151.1 (q, J = 44.2 Hz), 141.1 (s), 135.5 (q, J = 1.2 Hz), 134.9 (s), 129.2 (s), 127.7 (s), 127.1 (s), 116.4 (q, J = 270.8 Hz). IR (KBr): ν 3180, 2795, 2048, 1613, 1597, 1485, 1377, 1242, 1155, 1091, 937, 834, 732, 548, 508 cm⁻¹. GC-MS m/z 247 (M⁺). HRMS (EI) m/z: calcd. for C₁₀H₅ClF₃NO: 247.0012; found: 247.0003.

4-(4-Bromophenyl)-2-(trifluoromethyl)oxazole (3m)

Obtained as a white solid in 61% yield (178 mg). M.p. 32–33 °C. R_f (n-pentane) = 0.73. ¹H NMR (400 MHz, CDCl₃) δ 8.05 (s, 1H), 7.65 (d, J = 8.5 Hz, 2H), 7.58 (d, J = 8.5 Hz, 2H). ¹⁹F NMR (376 MHz, CDCl₃) δ -65.9 (s, 3F). ¹³C NMR (101 MHz, CDCl₃) δ 151.1 (q, J = 44.2 Hz), 141.2 (s), 135.6 (q, J = 1.2 Hz), 132.2 (s), 128.2 (s), 127.3 (s), 123.2 (s), 116.4 (q, J = 270.8 Hz). IR (KBr): ν 2244, 1596, 1481, 1376, 1243, 1207, 1159, 1126, 954, 938, 832, 549 cm⁻¹. GC-MS m/z 290 (M⁺). HRMS (EI) m/z: calcd. for C₁₀H₅BrF₃NO: 290.9507; found: 290.9503.

4-([1,1'-Biphenyl]-4-yl)-2-(trifluoromethyl)oxazole (3n)

Obtained as a white solid in 97% yield (280 mg). M.p.146–147 °C. R_f (n-pentane) = 0.45. ¹H NMR (400 MHz, CDCl₃) δ 8.09 (s, 1H), 7.87 (d, J = 8.0 Hz, 2H), 7.71 (d, J = 8.0 Hz, 2H), 7.66 (d, J = 8.0 Hz, 2H), 7.50 (t, J = 7.6 Hz, 2H), 7.41 (t, J = 7.8 Hz, 1H). ¹⁹F NMR (376 MHz, CDCl₃) δ -65.8 (s, 3F). ¹³C NMR (101 MHz, CDCl₃) δ 151.0 (q, J = 44.2 Hz), 141.9 (s), 141.8 (s), 140.3 (s), 135.4 (q, J = 1.2 Hz), 128.9 (s), 128.2 (s), 127.7 (s), 127.6 (s), 127.1 (s), 126.3 (s), 116.5 (q, J = 270.6 Hz). IR (KBr): ν 3036, 2209, 2013, 1581, 1483, 1385, 1245, 1202, 1130, 957, 841, 761, 551 cm⁻¹. GC-MS m/z 289 (M⁺). HRMS (EI) m/z: calcd. for C₁₆H₁₀F₃NO: 289.0714; found: 289.0711.

4-(Naphthalen-2-yl)-2-(trifluoromethyl)oxazole (30)

Obtained as a white solid in 64% yield (168 mg). M.p. 99–100 °C. R_f (n-pentane) = 0.42. ¹H NMR (400 MHz, CDCl₃) δ 8.35 (s, 1H), 8.15 (s, 1H), 7.98 – 7.86 (m, 3H), 7.80 (d, J = 8.5 Hz, 1H), 7.62 – 7.50 (m, 2H). ¹⁹F NMR (376 MHz, CDCl₃) δ -65.8 (s, 3F). ¹³C NMR (101 MHz, CDCl₃) δ 151.1 (q, J = 44.2 Hz), 142.2 (s), 135.7 (q, J = 1.2 Hz), 133.5 (s), 133.4 (s), 128.8 (s), 128.4 (s), 127.8 (s), 126.8 (s), 126.7 (s), 126.5 (s), 125.2 (s), 123.2 (s), 116.5 (q, J = 270.7 Hz). IR (KBr): v 2251, 2155, 1381, 1247, 1209, 1163, 1124, 953, 902, 811, 476 cm⁻¹. GC-MS m/z 263 (M⁺). HRMS (EI) m/z: calcd. for C₁₄H₈F₃NO: 263.0558; found: 263.0564.

4-(3,4-Dimethylphenyl)-2-(trifluoromethyl)oxazole (3p)

Obtained as a white solid in 56% yield (136 mg). M.p. 28–29 °C. R_f (n-pentane) = 0.67. ¹H NMR (400 MHz, CDCl₃) δ 8.00 (s, 1H), 7.58 (s, 1H), 7.50 (dd, J = 7.8, 1.6

Hz, 1H), 7.22 (d, J = 7.8 Hz, 1H), 2.34 (s, 3H), 2.33 (s, 3H). ¹⁹F NMR (376 MHz, CDCl₃) δ -65.8 (s, 3F). ¹³C NMR (101 MHz, CDCl₃) δ 150.8 (q, J = 43.9 Hz), 142.2 (s), 137.8 (s), 137.3 (s), 134.9 (q, J = 1.3 Hz), 130.2 (s), 126.9 (s), 126.7 (s), 123.2 (s), 116.5 (q, J = 270.7 Hz), 19.7 (s), 19.6 (s). IR (KBr): v 2973, 2195, 1583, 1492, 1385, 1242, 1206, 1158, 1123, 952, 862, 820, 548 cm⁻¹. GC-MS m/z 241 (M⁺). HRMS (EI) m/z: calcd. for C₁₂H₁₀F₃NO: 241.0714; found: 241.0718.

4-(Benzo[d][1,3]dioxol-5-yl)-2-(trifluoromethyl)oxazole (3q)

Obtained as a white solid in 89% yield (229 mg). M.p. 79–80 °C. R_f (n-pentane/ethyl acetate = 15:1) = 0.57. ¹H NMR (400 MHz, CDCl₃) δ 7.94 (s, 1H), 7.32 – 7.27 (m, 1H), 7.23 (s, 1H), 6.89 (d, J = 8.1 Hz, 1H), 6.04 (s, 2H). ¹⁹F NMR (376 MHz, CDCl₃) δ -65.9 (s, 3F). ¹³C NMR (101 MHz, CDCl₃) δ 150.8 (q, J = 43.9 Hz), 148.3 (s), 148.2 (s), 141.9 (s), 134.6 (q, J = 1.2 Hz), 123.3 (s), 119.9 (s), 116.4 (q, J = 270.7 Hz), 108.8 (s), 106.3 (s), 101.4 (s). IR (KBr): v 2853, 1586, 1505, 1483, 1448, 1383, 1287, 1235, 1198, 1124, 951, 873, 767, 682 cm⁻¹. GC-MS m/z 257 (M⁺). HRMS (EI) m/z: calcd. for C₁₁H₆F₃NO₃: 257.0300; found: 257.0304.

4-(Thiophen-2-yl)-2-(trifluoromethyl)oxazole (3r)

Obtained as a white solid in 72% yield (158 mg). M.p. 45–46 °C. R_f (n-pentane) = 0.52. 1 H NMR (400 MHz, CDCl₃) δ 7.96 (s, 1H), 7.50 – 7.43 (m, 1H), 7.39 (d, J = 5.0 Hz, 1H), 7.12 (dd, J = 4.7, 3.9 Hz, 1H). 19 F NMR (376 MHz, CDCl₃) δ -65.8 (s, 3F). 13 C NMR (101 MHz, CDCl₃) δ 150.9 (q, J = 44.3 Hz), 137.2 (s), 134.5 (q, J = 1.2 Hz), 131.4 (s), 127.9 (s), 126.3 (s), 125.6 (s), 116.3 (q, J = 271.0 Hz). IR (KBr): ν 3160,

2926, 2189, 1381, 1251, 1206, 1160, 1100, 952, 849, 701, 489 cm⁻¹. GC-MS m/z 218 (M⁺). HRMS (EI) m/z: calcd. for C₈H₄F₃NOS: 218.9966; found: 218.9962.

$\hbox{$4$-(5-Methylthiophen-2-yl)-2-(trifluoromethyl)oxazole (3s)$}$

Obtained as a white solid in 66% yield (154 mg). M.p. 46–47 °C. R_f (n-pentane) = 0.42. ¹H NMR (400 MHz, CDCl₃) δ 7.87 (s, 1H), 7.25 (d, J = 3.5 Hz, 1H), 6.76 (d, J = 3.5 Hz, 1H), 2.54 (s, 3H). ¹⁹F NMR (376 MHz, CDCl₃) δ -65.8 (s, 3F). ¹³C NMR (101 MHz, CDCl₃) δ 150.7 (q, J = 44.2 Hz), 141.1 (s), 137.4 (s), 133.9 (q, J = 1.3 Hz), 128.9 (s), 126.0 (s), 125.7 (s), 116.4 (q, J = 270.9 Hz), 15.3 (s). IR (KBr): v 3139, 2926, 2050, 1979, 1585, 1467, 1394, 1254, 1140, 1096, 955, 811, 786, 512 cm⁻¹. GC-MS m/z 233 (M⁺). HRMS (EI) m/z: calcd. for C₉H₆F₃NOS: 233.0122; found: 233.0124.

4-(Benzo[b]thiophen-2-yl)-2-(trifluoromethyl)oxazole (3t)

Obtained as a white solid in 62% yield (167 mg). M. p. 118–119 °C. R_f (n-pentane) = 0.35. ¹H NMR (400 MHz, acetone- d_6) δ 8.79 (s, 1H), 8.00 – 7.95 (m, 1H), 7.92 – 7.88 (m, 1H), 7.87 (s, 1H), 7.55 – 7.36 (m, 2H). ¹⁹F NMR (376 MHz, acetone- d_6) δ -66.7 (s, 3F). ¹³C NMR (101 MHz, acetone- d_6) δ 150.3 (q, J = 44.0 Hz), 139.9 (s), 139.5 (s), 137.8 (q, J = 1.0 Hz), 137.0 (s), 131.6 (s), 125.3 (s), 124.9 (s), 124.1 (s), 122.4 (s), 122.3 (s), 116.6 (q, J = 269.9 Hz). IR (KBr): v 2253, 1637, 1517, 1380, 1208, 1126, 1100, 953, 867, 525, 478 cm⁻¹. GC-MS m/z 269 (M⁺). HRMS (EI) m/z: calcd. for $C_{12}H_6F_3NOS$: 269.0122; found: 269.0123.

5-Methyl-4-phenyl-2-(trifluoromethyl)oxazole (3u)

Obtained as a white liquid in 76% yield (173 mg). R_f (n-pentane) = 0.65. ¹H NMR (400 MHz, CDCl₃) δ 7.71 (d, J = 7.4 Hz, 2H), 7.49 (t, J = 7.4 Hz, 2H), 7.40 (t, J = 7.4 Hz, 1H), 2.63 (s, 3H). ¹⁹F NMR (376 MHz, CDCl₃) δ -65.8 (s, 3F). ¹³C NMR (101 MHz, CDCl₃) δ 148.5 (q, J = 43.8 Hz), 146.7 (q, J = 0.9 Hz), 136.0 (s), 130.6 (s), 128.8 (s), 128.2 (s), 126.9 (s), 116.7 (q, J = 270.3 Hz), 11.8 (s). IR (KBr): v 2927, 1587, 1495, 1446, 1397, 1371, 1349, 1198, 1144, 1118, 972, 771, 734, 662 cm⁻¹. GC-MS m/z 227 (M⁺). HRMS (EI) m/z: calcd. for C₁₁H₈F₃NO: 227.0558; found: 227.0553.

5-Methyl-4-(p-tolyl)-2-(trifluoromethyl)oxazole (3v)

Obtained as a white liquid in 82% yield (198 mg). R_f (n-pentane) = 0.72. ¹H NMR (400 MHz, CDCl₃) δ 7.59 (d, J = 8.1 Hz, 2H), 7.29 (d, J = 8.1 Hz, 2H), 2.62 (s, 3H), 2.43 (s, 3H). ¹⁹F NMR (376 MHz, CDCl₃) δ -65.8 (s, 3F). ¹³C NMR (101 MHz, CDCl₃) δ 148.4 (q, J = 43.7 Hz), 146.3 (q, J = 1.2 Hz), 138.1 (s), 136.1 (s), 129.5 (s), 127.7 (s), 126.8 (s), 116.7 (q, J = 270.3 Hz), 21.2 (s), 11.8 (s). IR (KBr): v 2926, 1589, 1513, 1399, 1371, 1346, 1199, 1149, 1121, 1031, 972, 759, 733, 692 cm⁻¹. GC-MS m/z 241 (M⁺). HRMS (EI) m/z: calcd. for C₁₂H₁₀F₃NO: 241.0714; found: 241.0710.

4-(4-Methoxyphenyl)-5-methyl-2-(trifluoromethyl)oxazole (3w)

Obtained as a white solid in 82% yield (212mg). M.p. 62–63 °C. R_f (n-pentane) = $0.60.^{1}$ H NMR (400 MHz, CDCl₃) δ 7.61 (d, J = 8.6 Hz, 2H), 6.99 (d, J = 8.6 Hz, 2H), 3.86 (s, 3H), 2.59 (s, 3H). ¹⁹F NMR (376 MHz, CDCl₃) δ -65.9 (s, 3F). ¹³C NMR (101 MHz, CDCl₃) δ 159.6 (s), 148.3 (q, J = 43.6 Hz), 145.7 (q, J = 1.0 Hz), 135.8 (s), 128.2 (s), 123.1 (s), 116.7 (q, J = 270.2 Hz), 114. 2 (s), 55.2 (s), 11.7 (s). IR (KBr): v 2749, 2243, 1607, 1590, 1511, 1464, 1309, 1295, 1175, 1106, 956, 834, 786, 534 cm⁻¹. GC-MS m/z 257 (M⁺). HRMS (EI) m/z: calcd. for $C_{12}H_{10}F_3NO_2$: 257.0664; found: 257.0662.

4-(3-Methoxyphenyl)-5-methyl-2-(trifluoromethyl)oxazole (3x)

Obtained as a white liquid in 68% yield (175 mg). R_f (n-pentane) = 0.45. ¹H NMR (400 MHz, CDCl₃) δ 7.39 (t, J = 7.9 Hz, 1H), 7.26 (s, 1H), 7.25 (d, J = 7.3 Hz, 1H), 7.00 – 6.89 (m, 1H), 3.89 (s, 3H), 2.64 (s, 3H). ¹⁹F NMR (376 MHz, CDCl₃) δ -65.8 (s, 3F). ¹³C NMR (101 MHz, CDCl₃) δ 159.9 (s), 148.4 (q, J = 43.8 Hz), 146.9 (q, J = 1.2 Hz), 135.9 (s), 131.9 (s), 129.8 (s), 119.2 (s), 116.6 (q, J = 270.4 Hz), 113.9 (s), 112.4 (s), 55.4 (s), 12.2 (s). IR (KBr): v 2926, 2623, 1579, 1492, 1465, 1447, 1396, 1370, 1287, 1144, 1028, 972, 849, 738, 553 cm⁻¹. GC-MS m/z 257 (M⁺). HRMS (EI) m/z: calcd. for C₁₂H₁₀F₃NO₂: 257.0664; found: 257.0671.

4-(4-(Benzyloxy)phenyl)-5-methyl-2-(trifluoromethyl)oxazole (3y)

Obtained as a white solid in 74% yield (229 mg). M.p. 87–88 °C. R_f (n-pentane/ethyl acetate = 15:1) = 0.65. ¹H NMR (400 MHz, CDCl₃) δ 7.63 (d, J = 8.5 Hz, 2H), 7.53 – 7.34 (m, 5H), 7.09 (d, J = 8.5 Hz, 2H), 5.14 (s, 2H), 2.61 (s, 3H). ¹⁹F NMR (376 MHz, CDCl₃) δ -65.8 (s, 3F). ¹³C NMR (101 MHz, CDCl₃) δ 158.8 (s), 148.4 (q, J = 43.7 Hz), 145.7 (q, J = 1.1 Hz), 136.8 (s), 135.8 (s), 128.7 (s), 128.2 (s), 128.1 (s), 127.5 (s), 123.4 (s), 116.7 (q, J = 270.2 Hz), 115.2 (s), 70.1 (s), 11.8 (s). IR (KBr): v 2978, 2235, 1606, 1590, 1509, 1454, 1371, 1349, 1291, 1123, 957, 833, 761, 534 cm⁻¹. GC-MS m/z 333 (M⁺). HRMS (EI) m/z: calcd. for C₁₈H₁₄F₃NO₂: 333.0977; found: 333.0969.

4-(4-Fluorophenyl)-5-methyl-2-(trifluoromethyl)oxazole (3z)

Obtained as a white solid in 47% yield (116 mg). M.p. 29–30 °C. R_f (n-pentane) = 0.75. 1 H NMR (400 MHz, CDCl₃) δ 7.71 – 7.58 (m, 2H), 7.24 – 7.08 (m, 2H), 2.60 (s, 3H). 19 F NMR (376 MHz, CDCl₃) δ -65.9 (s, 3F), -113.2 – -113.3 (m, 1F). 13 C NMR (101 MHz, CDCl₃) δ 163.8 (s), 161.3 (s), 148.5 (q, J = 43.9 Hz), 146.5 (q, J = 1.2 Hz), 135.2 (s), 128.6 (d, J = 8.3 Hz), 126.7 (d, J = 3.3 Hz), 116.6 (q, J = 270.3 Hz), 115.9 (s), 115.7 (s), 11.7 (s). IR (KBr): v 2183, 2050, 1607, 1592, 1399, 1371, 1346, 1204, 1152, 1120, 1025, 973, 840, 760, 528 cm⁻¹. GC-MS m/z 245 (M⁺). HRMS (EI) m/z: calcd. for C₁₁H₇F₄NO: 245.0464; found: 245.0458.

Obtained as a white solid in 74% yield (194 mg). M.p. 42–43 °C. R_f (n-pentane) = 0.68. ¹H NMR (400 MHz, CDCl₃) δ 7.61 (d, J = 8.5 Hz, 2H), 7.42 (d, J = 8.5 Hz, 2H),

2.61 (s, 3H). ¹⁹F NMR (376 MHz, CDCl₃) δ -65.9 (s, 3F). ¹³C NMR (101 MHz, CDCl₃) δ 148.6 (q, J = 43.9 Hz), 146.9 (q, J = 1.2 Hz), 135.1 (s), 134.1 (s), 129.1 (s), 128.9 (s), 128.0 (s), 116.6 (q, J = 270.4 Hz), 11.8 (s). IR (KBr): v 2250, 1604, 1588, 1584, 1492, 1379, 1371, 1345, 1200, 1150, 1120, 972, 833, 762, 554 cm⁻¹. GC-MS m/z 261 (M⁺). HRMS (EI) m/z: calcd. for C₁₁H₇ClF₃NO: 261.0168; found: 261.0164.

4-(3-Chlorophenyl)-5-methyl-2-(trifluoromethyl)oxazole (3ab)

Obtained as a white liquid in 35% yield (92 mg). R_f (n-pentane) = 0.70. 1 H NMR (400 MHz, CDCl₃) δ 7.69 (s, 1H), 7.55 (d, J = 7.5 Hz, 1H), 7.44 – 7.31 (m, 2H), 2.63 (s, 3H). 19 F NMR (376 MHz, CDCl₃) δ -65.9 (s, 3F). 13 C NMR (101 MHz, CDCl₃) δ 148.6 (q, J = 44.0 Hz), 147.3 (q, J = 0.9 Hz), 134.8 (s), 132.3 (s), 130.0 (s), 128.2 (s), 126.8 (s), 124.8 (s), 116.5 (q, J = 270.4 Hz), 11.9 (s). IR (KBr): v 2250, 1608, 1598, 1580, 1472, 1369, 1348, 1205, 1145, 952, 853, 755, 558 cm $^{-1}$. GC-MS m/z 261 (M $^+$) HRMS (ESI) m/z: calcd. for C₁₁H₇ClF₃NO: 261.0168; found: 261.0164.

4-(4-Bromophenyl)-5-methyl-2-(trifluoromethyl)oxazole (3ac)

Obtained as a white solid in 66% yield (210 mg). M.p. 53–54 °C. R_f (n-pentane) = 0.72. 1 H NMR (400 MHz, CDCl₃) δ 7.63 – 7.48 (m, 4H), 2.61 (s, 3H). 19 F NMR (376 MHz, CDCl₃) δ -65.9 (s, 3F). 13 C NMR (101 MHz, CDCl₃) δ 148.6 (q, J = 44.0 Hz), 146.9 (q, J = 1.1 Hz), 135.1 (s), 131.9 (s), 129.5 (s), 128.3 (s), 122.3 (s), 116.5 (q, J = 270.4 Hz), 11.9 (s). IR (KBr): v 2842, 2236, 1819, 1602, 1582, 1487, 1394, 1346, 1202, 1007, 957, 831, 765, 521 cm⁻¹. GC-MS m/z 304 (M⁺). HRMS (EI) m/z: calcd. for $C_{11}H_7BrF_3NO$: 304.9663; found: 304.9668.

5-Ethyl-4-phenyl-2-(trifluoromethyl)oxazole (3ad)

Obtained as a white liquid in 56% yield (135 mg). R_f (n-pentane) = 0.52. ¹H NMR (400 MHz, CDCl₃) δ 7.72 – 7.66 (m, 2H), 7.50 (t, J = 7.6 Hz, 2H), 7.40 (t, J = 7.6 Hz, 1H), 3.01 (q, J = 7.5 Hz, 2H), 1.40 (t, J = 7.5 Hz, 2H). ¹⁹F NMR (376 MHz, CDCl₃) δ -65.8 (s, 3F). ¹³C NMR (101 MHz, CDCl₃) δ 151.7 (q, J = 1.2 Hz), 148.6 (q, J = 43.7 Hz), 135.4 (s), 130.7 (s), 128.8 (s), 128.3 (s), 127.1 (s), 116.7 (q, J = 270.3 Hz), 19.5 (s), 12.1 (s). IR (KBr): v 2981, 2875, 2164, 1584, 1495, 1447, 1391, 1377, 1271, 1148, 1072, 989, 969, 772, 562 cm⁻¹. GC-MS m/z 241 (M⁺). HRMS (EI) m/z: calcd. for $C_{12}H_{10}F_3NO$: 241.0714; found: 241.0717.

4-(4-Methoxyphenyl)-5-phenyl-2-(trifluoromethyl)oxazole (3ae)

Obtained as a colorless oil in 48% yield (138 mg). M.p. 73–74 °C. R_f (n-pentane/ethyl acetate = 15:1) = 0.50. ¹H NMR (400 MHz, CDCl₃) δ 7.76 – 7.64 (m, 4H), 7.50 – 7.41 (m, 6H). ¹⁹F NMR (376 MHz, CDCl₃) δ -65.7 (s, 3F). ¹³C NMR (101 MHz, CDCl₃) δ 149.2 (q, J = 43.9 Hz), 148.0 (q, J = 1.2 Hz), 136.0 (s), 130.8 (s), 129.9 (s), 129.0 (s), 128.9 (s), 128.8 (s), 128.0 (s), 127.3 (s), 127.1 (s), 116.7 (q, J = 270.7 Hz). IR (KBr): v 3062, 1580, 1504, 1482, 1445, 1383, 1354, 1206, 1145, 1120, 1073, 970, 763, 734, 690, 565 cm⁻¹. GC-MS m/z 288 (M⁺). HRMS (EI) m/z: calcd. for $C_{16}H_{10}F_3NO$: 289.0714; found: 289.0711.

4-(4-Methoxyphenyl)-5-phenyl-2-(trifluoromethyl)oxazole (3af)

Obtained as a white solid in 52% yield (166 mg). M.p. 113–114 °C. R_f (n-pentane/ethyl acetate = 15:1) = 0.63. ¹H NMR (400 MHz, CDCl₃) δ 7.76 – 7.55 (m, 4H), 7.51 – 7.37 (m, 3H), 6.96 (d, J = 8.6 Hz, 2H), 3.88 (s, 3H). ¹⁹F NMR (376 MHz, CDCl₃) δ -65.7 (s, 3F). ¹³C NMR (101 MHz, CDCl₃) δ 160.1 (s), 149.0 (q, J = 44.0 Hz), 147.2 (q, J = 1.0 Hz), 135.7 (s), 129.7 (s), 129.4 (s), 128.9 (s), 127.5 (s), 126.9 (s), 123.1 (s), 116.7 (q, J = 270.6 Hz), 114.2 (s), 55.3 (s). IR (KBr): v 2839, 2182, 2025, 1616, 1515, 1447, 1355, 1251, 1209, 972, 836, 718, 565 cm⁻¹. GC-MS m/z 319 (M⁺). HRMS (EI) m/z: calcd. for C₁₇H₁₂F₃NO₂: 319.0820; found: 319.0824.


4-Phenyl-2-(trifluoromethyl)-5-vinyloxazole (3ag)

Obtained as a colorless oil in 38% yield (90 mg). R_f (n-pentane) = 0.55. ¹H NMR (400 MHz, CDCl₃) δ 7.44 – 7.34 (m, 5H), 7.31 (s, 1H), 6.44 (d, J = 21.7 Hz, 2H). ¹⁹F NMR (376 MHz, CDCl₃) δ -68.9 (s, 3F). ¹³C NMR (101 MHz, CDCl₃) δ 137.2 (s), 132.3 (s), 128.9 (s), 128.1 (s), 127.9 (s), 121.4 (q, J = 4.7 Hz), 117.3 (s), 115.5 (q, J = 288.0 Hz), 114.6 (s). IR (KBr): v 2925, 1752, 1602, 1511, 1477, 1404, 1363, 1293, 1217, 1153, 1110, 892, 865, 824, 757, 694, 675, 586 cm⁻¹. GC-MS m/z 239 (M⁺). HRMS (EI) m/z: calcd. for C₁₂H₈F₃NO: 239.0558; found: 239.0553.

Crystal structure analyses

The suitable crystals of **3j** (CCDC 1835965) were mounted on quartz fibers and X-ray data collected on a Bruker AXS APEX diffractometer, equipped with a CCD detector at -50 °C, using MoKα radiation (λ 0.71073 Å). The data was corrected for Lorentz and polarisation effect with the **SMART** suite of programs and for absorption effects with SADABS. Structure solution and refinement were carried out with the SHELXTL suite of programs. The structure was solved by direct methods to locate the heavy atoms, followed by difference maps for the light non-hydrogen atoms.

ORTEP diagrams




ORTEP diagram of compound 3j. Thermal ellipsoids are drawn at 40% probability

References:

- 1. P. C. Too, Y.-F. Wang and S. Chiba, *Org. Lett.*, 2010, **12**, 5688-5691.
- 2. J. Ke, Y. Tang, H. Yi, Y. Li, Y. Cheng, C. Liu and A. Lei, *Angew. Chem. Int. Ed.*, 2015, **54**, 6604-6607.
- 3. H. Huang, J. Cai, X. Ji, F. Xiao, Y. Chen and G.-J. Deng, *Angew. Chem. Int. Ed.*, 2016, **55**, 307-311.
- X. Tang, J. Yang, Z. Zhu, M. Zheng, W. Wu and H. Jiang, J. Org. Chem., 2016,
 81, 11461-11466.
- C. Zhu, R. Zhu, H. Zeng, F. Chen, C. Liu, W. Wu and H. Jiang, *Angew. Chem. Int. Ed.*, 2017, 56, 13324-13328.
- 6. H. Huang, J. Cai, H. Xie, J. Tan, F. Li and G.-J. Deng, *Org. Lett.*, 2017, **19**, 3743-3746.
- 7. SHELXTL version 5.03; Bruker Analytical X-ray Systems, Madison, WI, 1997.


Copies of ¹H NMR, ¹³C NMR and ¹⁹F NMR spectra ¹⁹F NMR spectrum of **3a** in CDCl₃






10 0 -10 -20 -30 -40 -50 -60 -70 -80 -90 -100 -110 -120 -130 -140 -150 -160 -170 -180 -190 -200 -210

¹H NMR spectrum of 3a in CDCl₃






¹³C NMR spectrum of 3a in CDCl₃









¹⁹F NMR spectrum of 3b in CDCl₃

--65.83




¹H NMR spectrum of **3b** in CDCl₃






¹³C NMR spectrum of **3b** in CDCl₃






¹⁹F NMR spectrum of 3c in CDCl₃




¹H NMR spectrum of 3c in CDCl₃







^{13}C NMR spectrum of 3c in CDCl $_3$







^{19}F NMR spectrum of 3d in CDCl₃






¹H NMR spectrum of 3d in CDCl₃







¹³C NMR spectrum of 3d in CDCl₃














¹H NMR spectrum of 3e in CDCl₃









^{13}C NMR spectrum of 3e in CDCl $_3$







^{19}F NMR spectrum of 3f in CDCl₃






¹H NMR spectrum of 3f in CDCl₃






 ^{13}C NMR spectrum of 3f in CDCl₃







 ^{19}F NMR spectrum of 3g in CDCl $_3$






 ^{1}H NMR spectrum of 3g in CDCl $_{3}$





¹³C NMR spectrum of 3g in CDCl₃





¹⁹F NMR spectrum of 3h in CDCl₃




-100 -110 -120 -130 -140

-70 -80


¹H NMR spectrum of 3h in CDCl₃







^{13}C NMR spectrum of 3h in CDCl₃







 ^{19}F NMR spectrum of 3i in CDCl $_3$






¹**H NMR** spectrum of **3i** in CDCl₃






¹³C NMR spectrum of 3i in CDCl₃







¹⁹F NMR spectrum of 3j in CDCl₃




¹H NMR spectrum of 3j in CDCl₃






¹³C NMR spectrum of **3j** in CDCl₃







^{19}F NMR spectrum of 3k in CDCl $_3$





¹H NMR spectrum of 3k in CDCl₃






¹³C NMR spectrum of 3k in CDCl₃










¹⁹**F NMR** spectrum of **3l** in CDCl₃





¹H NMR spectrum of 3l in CDCl₃







¹³C NMR spectrum of 3l in CDCl₃

151. 74 151. 31 150. 43 150. 43 141. 12 135. 55 135. 54 135. 57 122. 20 122. 20 127. 72 112. 74 111. 15. 04






 $^{19}\!F$ NMR spectrum of 3m in CDCl $_3$






10 0 -10 -20 -30 -40 -50 -60 -70 -80 -90 -100 -110 -120 -130 -140 -150 -160 -170 -180 -190 -200 -210

¹H NMR spectrum of 3m in CDCl₃




8. 05 7. 66 7. 64 7. 59



13 C NMR spectrum of 3m in CDCl₃


151. 77 150. 89 150. 89 150. 89 150. 89 135. 60 135. 57 135. 57 132. 16 127. 33 127. 33 127. 33 127. 33 127. 33 127. 33 127. 33 127. 33 127. 33 127. 33







¹⁹F NMR spectrum of 3n in CDCl₃

N CF3





¹H NMR spectrum of 3n in CDCl₃






^{13}C NMR spectrum of 3n in CDCl $_3$







 ^{19}F NMR spectrum of 30 in CDCl $_3$





¹H NMR spectrum of 30 in CDCl₃






¹³C NMR spectrum of 30 in CDCl₃


151.78 150.91 15






¹⁹F NMR spectrum of 3p in CDCl₃

CF₃




¹H NMR spectrum of 3p in CDCl₃







^{13}C NMR spectrum of 3p in CDCl $_3$







^{19}F NMR spectrum of 3q in CDCl $_3$






¹H NMR spectrum of 3q in CDCl₃








151. 41 150. 98 150. 10 148. 34 114. 88 1134. 55 1134. 55 1134. 56 1134. 57 1120. 47 1115. 09 1115. 09 1106. 29





^{19}F NMR spectrum of 3r in CDCl $_3$

S CF₃


--65.81


-120

-150

-70


¹H NMR spectrum of 3r in CDCl₃







$^{13}C\ NMR$ spectrum of 3r in $CDCl_3$













¹H NMR spectrum of 3s in CDCl₃






¹³C NMR spectrum of 3s in CDCl₃







¹⁹**F NMR** spectrum of **3t** in acetone- d_6







1 H NMR spectrum of 3t in acetone- d_{6}








¹³C NMR spectrum of 3t in acetone- d_6














¹H NMR spectrum of 3u in CDCl₃







^{13}C NMR spectrum of 3u in CDCl $_3$







$^{19}F\ NMR$ spectrum of 3v in CDCl $_3$






¹H NMR spectrum of 3v in CDCl₃







 ^{13}C NMR spectrum of 3v in CDCl $_3$




^{19}F NMR spectrum of 3w in CDCl $_3$






¹H NMR spectrum of 3w in CDCl₃






^{13}C NMR spectrum of 3w in CDCl $_3$






^{19}F NMR spectrum of 3x in CDCl₃






¹H NMR spectrum of 3x in CDCl₃







^{13}C NMR spectrum of 3x in CDCl $_3$






¹⁹F NMR spectrum of 3y in CDCl₃






¹H NMR spectrum of 3y in CDCl₃




^{13}C NMR spectrum of 3y in CDCl $_3$






^{19}F NMR spectrum of 3z in CDCl $_3$






¹H NMR spectrum of 3z in CDCl₃







^{13}C NMR spectrum of 3z in CDCl $_3$






¹⁹F NMR spectrum of 3aa in CDCl₃






¹H NMR spectrum of 3aa in CDCl₃






13 C NMR spectrum of 3aa in CDCl $_3$







¹⁹F NMR spectrum of 3ab in CDCl₃






¹H NMR spectrum of 3ab in CDCl₃






¹³C NMR spectrum of **3ab** in CDCl₃







^{19}F NMR spectrum of 3ac in CDCl $_3$







¹H NMR spectrum of 3ac in CDCl₃






^{13}C NMR spectrum of 3ac in CDCl $_3$







^{19}F NMR spectrum of compound 3ad in CDCl $_3$




¹H NMR spectrum of compound **3ad** in CDCl₃







^{13}C NMR spectrum of compound 3ad in CDCl $_3$







 ^{19}F NMR spectrum of compound 3ae in CDCl $_3$





¹H NMR spectrum of compound 3ae in CDCl₃






77

13 C NMR spectrum of compound 3ae in CDCl $_3$







¹⁹F NMR spectrum of compound **3af** in CDCl₃




¹H NMR spectrum of compound 3af in CDCl₃







¹³C NMR spectrum of compound 3af in CDCl₃














¹H NMR spectrum of 3ag in CDCl₃






13 C NMR spectrum of 3ag in CDCl $_3$






^{19}F NMR spectrum of compound 5 in CDCl $_3$



$^{1}H\ NMR$ spectrum of compound 5 in CDCl $_{3}$





^{13}C NMR spectrum of compound 5 in CDCl $_3$

| 171.25 | 155.87 | 155.87 | 155.87 | 155.80 | 146.61 | 146.61 | 136.04 | 138.04 | 120.28 | 120.28 | 120.28 | 120.28 | 117.41 | 117.41 | 117.41 | 117.41 | 117.41 | 117.41 | 117.41 | 117.41 | 117.41 | 117.41 | 117.41 | 117.41 | 117.41 | 117.41 | 117.41 | 117.41 | 117.41 | 117.41 | 117.41 | 117.41 | 117.41 | 117.41 | 117.41 | 117.41 | 117.41 | 117.41 | 117.41 | 117.41 | 117.41 | 117.41 | 117.41 | 117.41 | 117.41 | 117.41 | 117.41 | 117.41 | 117.41 | 117.41 | 117.41 | 117.41 | 117.41 | 117.41 | 117.41 | 117.41 | 117.41 | 117.41 | 117.41 | 117.41 | 117.41 | 117.41 | 117.41 | 117.41 | 117.41 | 117.41 | 117.41 | 117.41 | 117.41 | 117.41 | 117.41 | 117.41 | 117.41 | 117.41 | 117.41 | 117.41 | 117.41 | 117.41 | 117.41 | 117.41 | 117.41 | 117.41 | 117.41 | 117.41 | 117.41 | 117.41 | 117.41 | 117.41 | 117.41 | 117.41 | 117.41 | 117.41 | 117.41 | 117.41 | 117.41 | 117.41 | 117.41 | 117.41 | 117.41 | 117.41 | 117.41 | 117.41 | 117.41 | 117.41 | 117.41 | 117.41 | 117.41 | 117.41 | 117.41 | 117.41 | 117.41 | 117.41 | 117.41 | 117.41 | 117.41 | 117.41 | 117.41 | 117.41 | 117.41 | 117.41 | 117.41 | 117.41 | 117.41 | 117.41 | 117.41 | 117.41 | 117.41 | 117.41 | 117.41 | 117.41 | 117.41 | 117.41 | 117.41 | 117.41 | 117.41 | 117.41 | 117.41 | 117.41 | 117.41 | 117.41 | 117.41 | 117.41 | 117.41 | 117.41 | 117.41 | 117.41 | 117.41 | 117.41 | 117.41 | 117.41 | 117.41 | 117.41 | 117.41 | 117.41 | 117.41 | 117.41 | 117.41 | 117.41 | 117.41 | 117.41 | 117.41 | 117.41 | 117.41 | 117.41 | 117.41 | 117.41 | 117.41 | 117.41 | 117.41 | 117.41 | 117.41 | 117.41 | 117.41 | 117.41 | 117.41 | 117.41 | 117.41 | 117.41 | 117.41 | 117.41 | 117.41 | 117.41 | 117.41 | 117.41 | 117.41 | 117.41 | 117.41 | 117.41 | 117.41 | 117.41 | 117.41 | 117.41 | 117.41 | 117.41 | 117.41 | 117.41 | 117.41 | 117.41 | 117.41 | 117.41 | 117.41 | 117.41 | 117.41 | 117.41 | 117.41 | 117.41 | 117.41 | 117.41 | 117.41 | 117.41 | 117.41 | 117.41 | 117.41 | 117.41 | 117.41 | 117.41 | 117.41 | 117.41 | 117.41 | 117.41 | 117.41 | 117.41 | 117.41 | 117.41 | 117.41 | 117.41 | 1

